WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Diamond V
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Biotechnology news | March 06, 2020
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection...
Medical
GE | June 20, 2022
With most hospitals around the world currently relying on manual “spot-checks” to monitor patient vitals, GE Healthcare unveils Portrait Mobile3, a wireless patient monitoring system that enables continuous monitoring throughout a patient’s stay. The system helps clinicians detect patient deterioration. Early detection of patient deterioration may help reduce length of stay and intensive care unit (ICU) admissions – and improve patient outcomes4. Portrait Mobile includes ...
Cell and Gene Therapy
Lunaphore and Nucleai | September 09, 2022
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies. “We are thrilled to announce the partnership with Lunaphore and...
Puma Biotechnology | September 21, 2022
Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...
Research, Medical
Whitepaper
Cell and Gene Therapy, Medical
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE